Congratulations to Drs. McCarter, Couts, and Medina on being selected by the NCCN as one of three projects to study oral decitabine (35 mg) and cedazuridine (100 mg).
Ross Camidge, MD, PhD discusses the role of targeted therapy and how it is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer.
The University of Colorado School of Medicine is listed No. 6 in primary care and No. 27 in research on the Best Medical School ranking by U.S. News and World Report.